Accessibility Menu
Supernus Pharmaceuticals logo

Supernus Pharmaceuticals(NASDAQ) SUPN

Current Price$46.92
Market Cap$2.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)+791%
5 Year+72%
1 Year+44%
1 Month+6%
Supernus Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 46.942026-07-22
Supernus Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.66%USD 47.732026-07-15
1 month+5.53%USD 44.482026-06-22
3 month-6.85%USD 50.392026-04-23
Year to date-5.55%USD 49.702025-12-31
1 year+43.68%USD 32.672025-07-22
3 year+53.35%USD 30.612023-07-21
5 year+72.13%USD 27.272021-07-23
Since inception+791.43%USD 5.372012-05-01

Supernus Pharmaceuticals Financials at a Glance

Market Cap

$2.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$776.83M

Net Income (TTM)

-$29.02M

EPS (TTM)

-$0.51

P/E Ratio

-93.51

Dividend

$0.00

Beta (Volatility)

0.62 (Low)

Price

$46.92

Volume

13,338

Open

$48.17

Previous Close

$46.92

Daily Range

$46.81 - $48.17

52-Week Range

$32.51 - $59.68

Estimated Earnings Date

Aug 4, 2026

SUPN News

SellAlert-Blue.png

What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year

Jonathan PoncianoMay 12, 2026
SellAlert-Green.png

Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year

Jonathan PoncianoMar 27, 2026
SellAlert-Red.png

Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back

Jonathan PoncianoDec 15, 2025
Scientists in a lab(1)

Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy

Alex CarchidiJun 10, 2023
Woman drawing big yellow fish about to eat small yellow fish

Why Supernus' Acquisition of Adamas Is a Smart Move

Keith SpeightsOct 21, 2021
GettyImages-659150976

Why Supernus Pharmaceuticals Stock Is Soaring Today

Prosper Junior BakinyApr 5, 2021
GettyImages-500536318

These 2 Scrappy Biotechs Could Skyrocket in April

Alex CarchidiApr 4, 2021
large pile of hundred dollar bills cash money savings rich

3 Healthcare Stocks That Could Be Millionaire-Makers

James HalleyMar 24, 2021
Page 1

SUPN: Motley Fool Moneyball Superscore

62

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Supernus Pharmaceuticals

Supernus makes medicines for brain and nerve disorders. These products help people manage ADHD and Parkinson's disease. The company serves patients needing specialized mental health care.

Medicines for Brain Health

  • ADHD Treatments: Non-stimulant capsules for adults and children six years and older; marketed under the brand name Qelbree to treat attention-deficit hyperactivity disorder (ADHD).
  • Parkinson's Disease Therapies: Medicines designed to manage motor issues and "off" episodes; includes brands such as GOCOVRI, APOKYN, XADAGO, and ONAPGO for Parkinson's disease (PD).
  • Depression Care: Oral medicine for adults experiencing postpartum depression (PPD); commercialized as ZURZUVAE in partnership with Biogen.
  • Epilepsy and Migraine: Extended-release products used to treat seizures and prevent migraine headaches; sold under the brand names Trokendi XR and Oxtellar XR.

Strategic Growth and Expansion

  • Acquired Sage Therapeutics, Inc. in July 2025 to expand into treatments for postpartum depression and major depressive disorder.
  • Launched ONAPGO in April 2025 as a new treatment for motor fluctuations in adults with advanced Parkinson's disease.
  • Expanded the label for Qelbree in January 2025 to include new clinical data on pharmacodynamics and use in breastfeeding mothers.
  • Entered a binding memorandum of understanding with Navitor Pharmaceuticals, Inc. in May 2025 to acquire assets for treatment-resistant depression.

Specialized Drug Delivery Tools

Supernus uses proprietary technologies like Microtrol and Solutrol to create extended-release versions of known drugs. These platforms help improve how patients take their medicine by maintaining steady medication levels in the blood.

Performance by the Numbers

  • Revenue reached $211.6 million in Q4 2025, up 21.5% year-over-year.
  • Gross profit was $188.6 million in Q4 2025, up 27.4% from Q4 2024.
  • Net loss was $4.1 million in Q4 2025, down 126.8% from the profit recorded in Q4 2024.
  • Free cash flow hit $19.4 million in Q4 2025, down 56% year-over-year.
  • Three major wholesalers collectively accounted for more than 76% of total product revenue in 2025.

Bottom Line

Supernus has transitioned from a developer to a commercial-stage firm with a broad central nervous system (CNS) portfolio. Its recent acquisition of Sage Therapeutics, Inc. and the launch of new Parkinson's therapies signal a focus on long-term portfolio diversification.

AI Generated • Apr 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

778

CEO

Jack A. Khattar, MBA

Website

www.supernus.com

Headquarters

Rockville, MD 20850, US

SUPN Financials

Key Financial Metrics (TTM)

Gross Margin

89.42%

Operating Margin

-5.37%

Net Income Margin

-3.74%

Return on Equity

-2.73%

Return on Capital

-3.34%

Return on Assets

-1.93%

Earnings Yield

-1.07%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

58.04M

Volume

13.34K

Avg. Volume

773.65K

Financials (TTM)

Gross Profit

$694.64M

Operating Income

-$41.71M

EBITDA

$51.75M

Operating Cash Flow

$83.26M

Capital Expenditure

-$1.01M

Free Cash Flow

$82.25M

Cash & ST Invst.

$384.24M

Total Debt

$40.90M

Supernus Pharmaceuticals Performance Analysis

Supernus Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 667,238,00015.1%
20232023-12-31USD 607,521,000-8.9%
20242024-12-31USD 661,817,0008.9%
20252025-12-31USD 718,952,0008.6%
Supernus Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3010.4%
Q32025-09-3016.1%
Q42025-12-3110.1%
Q12026-03-31-1.8%
Supernus Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.046.0%
20232023-12-31USD 0.02-97.7%
20242024-12-31USD 1.325469.6%
20252025-12-31USD -0.68N/A
Supernus Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30290.5%
Q32025-09-30-300.0%
Q42025-12-3191.0%
Q12026-03-3144.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$207.71M

+38.6%

Gross Profit

$184.31M

+37.5%

Gross Margin

88.74%

N/A

Market Cap

$2.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.57M

N/A

Employees

778

N/A

Net Income

-$2.29M

+80.6%

EBITDA

$20.19M

+13.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$384.24M

-17.1%

Total Debt

$40.90M

+26.6%

Accounts Receivable

$182.18M

+25.1%

Inventory

$87.06M

+76.2%

Long Term Debt

$30.27M

+14.8%

Short Term Debt

$10.64M

+79.1%

Return on Assets

-1.93%

N/A

Return on Invested Capital

-3.70%

N/A

Free Cash Flow

$66.52M

+119.8%

Operating Cash Flow

$66.52M

+117.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GRALGRAIL Inc.
$70.66-2.82%
HCMHUTCHMED (China) Limited
$11.12-0.54%
BHCBausch Health Companies Inc.
$4.56+0.88%
PRGOPerrigo Company plc
$10.47+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%

Questions About SUPN

What is the current price of Supernus Pharmaceuticals?

Supernus Pharmaceuticals is trading at $46.92 per share.

What is the 52-week range for Supernus Pharmaceuticals?

Over the past 52 weeks, Supernus Pharmaceuticals has traded between $32.51 and $59.68.

How much debt does Supernus Pharmaceuticals have?

As of the most recent reporting period, Supernus Pharmaceuticals reported total debt of $40.90M.

How much cash does Supernus Pharmaceuticals have on hand?

Supernus Pharmaceuticals reported $184.87M in cash and cash equivalents in its most recent financial results.

What is Supernus Pharmaceuticals’s dividend yield?

Supernus Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services